PMID- 32237273
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210602
IS  - 1099-0496 (Electronic)
IS  - 8755-6863 (Print)
IS  - 1099-0496 (Linking)
VI  - 55
IP  - 6
DP  - 2020 Jun
TI  - Improvements in frailty contribute to substantial improvements in quality of life 
      after lung transplantation in patients with cystic fibrosis.
PG  - 1406-1413
LID - 10.1002/ppul.24747 [doi]
AB  - BACKGROUND: While lung transplantation (LTx) improves health-related quality of 
      life (HRQL) in cystic fibrosis (CF), the determinants of this improvement are 
      unknown. In other populations, frailty-a syndrome of vulnerability to physiologic 
      stressors-is associated with disability and poor HRQL. We hypothesized that 
      improvements in frailty would be associated with improved disability and HRQL in 
      adults with CF undergoing LTx. METHODS: In a single-center prospective cohort 
      study from 2010 to 2017, assessments of frailty, disability, and HRQL were 
      performed before and at 3- and 6-months after LTx. We assessed frailty by the 
      short physical performance battery (SPPB). We assessed disability with the Lung 
      Transplant Valued Life Activities scale (LT-VLA) and HRQL by the Medical Outcomes 
      Study Short Form Physical and Mental Component Summary scales (SF12-PCS, -MCS), 
      the Airway Questionnaire 20-Revised (AQ20R), and the Euroqol 5D (EQ5D). We tested 
      the association of concurrent changes in frailty and lung function on disability 
      and HRQL by linear mixed-effects models adjusted for sex and body mass index. 
      RESULTS: Among 23 participants with CF, improvements in frailty and lung function 
      were independently associated with improved disability and some HRQL measures. 
      For example, each 1-point improvement in SPPB or 200 mL improvement in FEV1 was 
      associated with improved LT-VLA disability by 0.14 (95%CI: 0.08-0.20) and 0.07 
      (95%CI: 0.05-0.09) points and improved EQ5D by 0.05 (95%CI: 0.03 to 0.07) and 
      0.02 (95%CI: 0.01-0.03) points, respectively. CONCLUSION: Improvement in frailty 
      is a novel determinant of improved disability and HRQL in adults with CF 
      undergoing LTx.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Perez, Alyssa A
AU  - Perez AA
AUID- ORCID: 0000-0002-8062-7174
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Hays, Steven R
AU  - Hays SR
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Soong, Allison
AU  - Soong A
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Gao, Ying
AU  - Gao Y
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Greenland, John R
AU  - Greenland JR
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Leard, Lorriana E
AU  - Leard LE
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Shah, Rupal J
AU  - Shah RJ
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Golden, Jeffrey
AU  - Golden J
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Kukreja, Jasleen
AU  - Kukreja J
AD  - Department of Surgery, University of California San Francisco, San Francisco, 
      California.
FAU - Venado, Aida
AU  - Venado A
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Kleinhenz, Mary Ellen
AU  - Kleinhenz ME
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
FAU - Singer, Jonathan P
AU  - Singer JP
AUID- ORCID: 0000-0003-0224-7472
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      California.
LA  - eng
GR  - IK2 CX001034/CX/CSRD VA/United States
GR  - ORD IK2CX001034 (JRG)/RD/ORD VA/United States
GR  - K23 HL111115 (JPS)/HL/NHLBI NIH HHS/United States
GR  - I01 CX002011/CX/CSRD VA/United States
GR  - R01 HL151552/HL/NHLBI NIH HHS/United States
GR  - R01 HL134851/HL/NHLBI NIH HHS/United States
GR  - R01 HL134851 (JPS)/HL/NHLBI NIH HHS/United States
GR  - K23 HL111115/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200401
PL  - United States
TA  - Pediatr Pulmonol
JT  - Pediatric pulmonology
JID - 8510590
SB  - IM
MH  - Adult
MH  - Body Mass Index
MH  - Cystic Fibrosis/physiopathology/*therapy
MH  - Disabled Persons/statistics & numerical data
MH  - Female
MH  - Frailty/*therapy
MH  - Humans
MH  - Lung/physiology
MH  - *Lung Transplantation
MH  - Male
MH  - Prospective Studies
MH  - Quality of Life
MH  - Young Adult
PMC - PMC8048765
MID - NIHMS1687209
OTO - NOTNLM
OT  - cystic fibrosis
OT  - frailty
OT  - health related quality of life
OT  - lung transplantation
OT  - patient centered outcomes
COIS- Conflicts of Interest Statement: we have no conflicts of interest
EDAT- 2020/04/03 06:00
MHDA- 2020/12/01 06:00
PMCR- 2021/06/01
CRDT- 2020/04/03 06:00
PHST- 2019/08/10 00:00 [received]
PHST- 2020/03/07 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
PHST- 2021/06/01 00:00 [pmc-release]
AID - 10.1002/ppul.24747 [doi]
PST - ppublish
SO  - Pediatr Pulmonol. 2020 Jun;55(6):1406-1413. doi: 10.1002/ppul.24747. Epub 2020 
      Apr 1.